Artesunate (ART), a first‐line antimalarial drug [128], has recently been shown to alleviate SS through suppression of the TLR‐MyD88‐IRF7 signaling pathway and downregulating IFN‐α in pDCs, this finding has been dually validated in clinical specimens and NOD mouse experiments [128]. This evidence concerns the gene IFNA1 and synovial sarcoma.